Patients & Caregivers

Agios Clinical Trials

Agios has leveraged its core capabilities in cellular metabolism to build a product engine that is focused in the therapeutic areas of cancer and rare genetic disorders of metabolism.

DISEASE PROGRAM STUDY PHASE STATUS LEARN MORE
Acute Myeloid Leukemia ENASIDENIB Phase 3 IDHENTIFY Study – An Efficacy and Safety Study of enasidenib (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation Recruiting clinicaltrials.gov
Acute Myeloid Leukemia ENASIDENIB Phase 1/2 Study of Enasidenib in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation Active, not recruiting clinicaltrials.gov
Acute Myeloid Leukemia ENASIDENIB or IVOSIDENIB Phase 1b Safety Study of Ivosidenib or Enasidenib in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation Recruiting clinicaltrials.gov
Acute Myeloid Leukemia ENASIDENIB or IVOSIDENIB Phase 1/2 Safety and Efficacy Study of Oral Ivosidenib Plus Subcutaneous Azacitidine and Oral Enasidenib Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Recruiting clinicaltrials.gov
Acute Myeloid Leukemia IVOSIDENIB Phase 1 Study of Orally Administered Ivosidenib in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation Recruiting clinicaltrials.gov
Solid Tumors (including Glioma) IVOSIDENIB Phase 1 Study of Orally Administered Ivosidenib in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation Active, not recruiting clinicaltrials.gov
Cholangiocarcinoma IVOSIDENIB Phase 3 Study of Orally Administered Ivosidenib in Previously Treated Advanced Cholangiocarcinoma Patients With IDH1 Mutations Recruiting clinicaltrials.gov
claridhy.com
Acute Myeloid Leukemia IVOSIDENIB Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE) Recruiting clinicaltrials.gov
Solid Tumors (including Glioma) AG-881 Phase 1 Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation Recruiting clinicaltrials.gov
Solid Tumors ENASIDENIB Study of Orally Administered Enasidenib in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed clinicaltrials.gov
Pyruvate kinase deficiency AG-348 Phase 2 DRIVE PK Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency Active, not recruiting clinicaltrials.gov
drivepktrial.com
Pyruvate kinase deficiency AG-348 A Phase 1 SAD Study of AG-348 in Healthy Volunteers Completed clinicaltrials.gov
Pyruvate kinase deficiency AG-348 A Phase 1 MAD Study of AG-348 in Healthy Volunteers Completed clinicaltrials.gov
Pyruvate kinase deficiency Non-interventional Natural History Study of Pyruvate Kinase Deficiency – led by Boston Children's Active, not recruiting clinicaltrials.gov

The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.